Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™

Hongru Zhao; Zheman Xiao; Lei Zhang; Janet Ford; Shiying Zhong; Wenyu Ye; Jinnan Li; Antje Tockhorn-Heidenreich; Sarah Cotton; Chunfu Chen

doi:10.2147/JPR.S371887

Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™

J Pain Res. 2023 Feb 3:16:357-371. doi: 10.2147/JPR.S371887. eCollection 2023.

Authors

Hongru Zhao¹, Zheman Xiao², Lei Zhang³, Janet Ford⁴, Shiying Zhong³, Wenyu Ye⁴, Jinnan Li³, Antje Tockhorn-Heidenreich⁴, Sarah Cotton⁵, Chunfu Chen^{6

7}

Affiliations

¹ The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
² Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
³ Eli Lilly China, Shanghai, People's Republic of China.
⁴ Eli Lilly and Company, Indianapolis, IN, USA.
⁵ Adelphi Real World, Bollington, UK.
⁶ Department of Neurology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University Jinan, Jinan, People's Republic of China.
⁷ Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.

Abstract

Objective: This study assessed treatment patterns, disease burden, outcomes, and unmet needs among patients with episodic migraine (EM) in China using Adelphi Migraine Disease Specific Programme™ (DSP) real-world data.

Background: Migraine is a prevalent and debilitating neurological disorder which presents a major public health burden globally. Research on characteristics, disease burden, and treatment patterns in EM patients in China is limited.

Methods: Data were drawn from an existing data set Adelphi Migraine DSP, a point-in-time survey conducted in China (January-June 2014). Internists/neurologists completed patient record forms for the next 9 patients who consulted them in clinical practice; these same patients completed the 'patient self-completion questionnaires'. Descriptive analyses were used to assess key variables: patient demographics, treatment patterns (current acute and preventive medication [AM/PM]), effectiveness, issues with existing treatment, Migraine Disability Assessment (MIDAS) scores, and Work Productivity and Activity Impairment scores.

Results: Total of 125 internists/neurologists provided data on 1113 patients with EM (headache days/month <15). Mean (standard deviation [SD]) age was 43.8 (13.1) years; mean (SD) number of migraine days/month was 3.2 (1.7). AM was prescribed in 86.1% of patients (non-steroid anti-inflammatory drugs [NSAIDs]: 62.7%; triptans: 7.7%), PM in 38.5%, and both in 24.9% of patients. Approximately 55% of patients experienced ≥1 issue with their current AM or PM. Migraine-related symptoms (including nausea, photophobia, and phonophobia) were fully controlled in <50% of patients receiving NSAIDs (21.7-38.4%) or triptans (32.4-43.5%). Insufficient response to current AM (migraine headache fully resolved within 2 hours in ≤3/5 attacks) was reported by 42.5% of patients. Mild-to-severe disability was reported by 36.8% of patients with a mean (SD) MIDAS score of 5.8 (7.3). Overall, 58.0% of work time was impaired (including time missed and impairment while working).

Conclusion: This analysis suggests, despite existing treatment options, disease burden and unmet medical needs remain substantial in Chinese patients with EM.

Keywords: clinical practice; disease burden; episodic migraine; patient-reported outcomes; real-world.

Grants and funding

Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Migraine Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Eli Lilly and Company. The study described here using data from the Adelphi Migraine Disease Specific Programme was funded by Eli Lilly and Company. All data that support the findings of this study are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Sarah Cotton at sarah.cotton@adelphigroup.com.